CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population

Emma Kenney-Herbert, Talal Al-Mayhani, Sara G.M. Piccirillo, Joanna Fowler, Inmaculada Spiteri, Philip Jones, Colin Watts

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15 represented a credible stemcell marker in GB.Wefirst demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15–) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15–cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15– were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15– cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15–cells over time, and both CD15+ and CD15–cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior ofCD15+cellscomparedwithCD15–cells fromthesame patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15– states. Our data challenge the utility of CD15 as a cancer stem cell marker.

Original languageEnglish (US)
Pages (from-to)821-831
Number of pages11
JournalStem cells translational medicine
Volume4
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

Glioblastoma
Neoplastic Stem Cells
Population
Neoplasms
Transcriptome
Regeneration
Stem Cells
Cell Line
Growth
Research
In Vitro Techniques
Therapeutics

Keywords

  • Cancer
  • CD15
  • Glioblastoma
  • Hierarchy
  • SSEA1
  • Stem cell

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Kenney-Herbert, E., Al-Mayhani, T., Piccirillo, S. G. M., Fowler, J., Spiteri, I., Jones, P., & Watts, C. (2015). CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population. Stem cells translational medicine, 4(7), 821-831. https://doi.org/10.5966/sctm.2014-0047

CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population. / Kenney-Herbert, Emma; Al-Mayhani, Talal; Piccirillo, Sara G.M.; Fowler, Joanna; Spiteri, Inmaculada; Jones, Philip; Watts, Colin.

In: Stem cells translational medicine, Vol. 4, No. 7, 01.01.2015, p. 821-831.

Research output: Contribution to journalArticle

Kenney-Herbert, E, Al-Mayhani, T, Piccirillo, SGM, Fowler, J, Spiteri, I, Jones, P & Watts, C 2015, 'CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population', Stem cells translational medicine, vol. 4, no. 7, pp. 821-831. https://doi.org/10.5966/sctm.2014-0047
Kenney-Herbert E, Al-Mayhani T, Piccirillo SGM, Fowler J, Spiteri I, Jones P et al. CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population. Stem cells translational medicine. 2015 Jan 1;4(7):821-831. https://doi.org/10.5966/sctm.2014-0047
Kenney-Herbert, Emma ; Al-Mayhani, Talal ; Piccirillo, Sara G.M. ; Fowler, Joanna ; Spiteri, Inmaculada ; Jones, Philip ; Watts, Colin. / CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population. In: Stem cells translational medicine. 2015 ; Vol. 4, No. 7. pp. 821-831.
@article{af5aa8a65f1c41058d51d76285665d90,
title = "CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population",
abstract = "Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15 represented a credible stemcell marker in GB.Wefirst demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15–) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15–cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15– were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15– cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15–cells over time, and both CD15+ and CD15–cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior ofCD15+cellscomparedwithCD15–cells fromthesame patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15– states. Our data challenge the utility of CD15 as a cancer stem cell marker.",
keywords = "Cancer, CD15, Glioblastoma, Hierarchy, SSEA1, Stem cell",
author = "Emma Kenney-Herbert and Talal Al-Mayhani and Piccirillo, {Sara G.M.} and Joanna Fowler and Inmaculada Spiteri and Philip Jones and Colin Watts",
year = "2015",
month = "1",
day = "1",
doi = "10.5966/sctm.2014-0047",
language = "English (US)",
volume = "4",
pages = "821--831",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - CD15 expression does not identify a phenotypically or genetically distinct glioblastoma population

AU - Kenney-Herbert, Emma

AU - Al-Mayhani, Talal

AU - Piccirillo, Sara G.M.

AU - Fowler, Joanna

AU - Spiteri, Inmaculada

AU - Jones, Philip

AU - Watts, Colin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15 represented a credible stemcell marker in GB.Wefirst demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15–) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15–cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15– were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15– cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15–cells over time, and both CD15+ and CD15–cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior ofCD15+cellscomparedwithCD15–cells fromthesame patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15– states. Our data challenge the utility of CD15 as a cancer stem cell marker.

AB - Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15 represented a credible stemcell marker in GB.Wefirst demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15–) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15–cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15– were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15– cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15–cells over time, and both CD15+ and CD15–cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior ofCD15+cellscomparedwithCD15–cells fromthesame patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15– states. Our data challenge the utility of CD15 as a cancer stem cell marker.

KW - Cancer

KW - CD15

KW - Glioblastoma

KW - Hierarchy

KW - SSEA1

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84937000534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937000534&partnerID=8YFLogxK

U2 - 10.5966/sctm.2014-0047

DO - 10.5966/sctm.2014-0047

M3 - Article

C2 - 26019225

AN - SCOPUS:84937000534

VL - 4

SP - 821

EP - 831

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 7

ER -